CR-CHOP+X in Previously Untreated DEL

NCT06701357 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

49

Enrollment

OTHER

Sponsor class

Conditions

DLBCL

Interventions

DRUG: CR-CHOP+PD1 inhibitor
DRUG: CR-CHOP + Orelabrutinib
DRUG: CR-CHOP + decitabine

Sponsor

Ruijin Hospital